-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On January 6, 2022, Amgen and Generate Biomedicines announced a research collaboration agreement
.
The two companies will leverage the artificial intelligence (AI) drug discovery technology platform developed by Generate to develop protein therapeutics against five clinical targets across multiple therapeutic areas and treatment modalities
Generate is committed to combining AI technology, biology, and bioengineering to build machine algorithms to extract statistical rules that control protein function and biological system interactions
.
The company's machine learning algorithms analyze hundreds of millions of known proteins, looking for statistical features that link amino acid sequence, structure and function
The immune system can recognize and eliminate foreign proteins, limiting the ability of many biologicals to function in the body
.
The Generative Biology platform can re-encode protein sequences that preserve their structure and function while avoiding the activation of unwanted immune responses
Under the terms of the agreement, Amgen will make an upfront payment of $50 million for the first five projects
.
For each project, Amgen will pay up to $370 million in milestone payments and royalties on future products, for a potential total of more than $1.
References:
References:[1] Amgen And Generate Biomedicines Announce Multi-Target, Multi-Modality Research Collaboration Agreement.
[1] Amgen And Generate Biomedicines Announce Multi-Target, Multi-Modality Research Collaboration Agreement.
[2] Amgen Chooses Generate In $1.
9B Biobucks Deal To Churn Out Up To 10 Multispecific Drugs.
Retrieved January 6, 2022, from https:// -biobucks-deal-to-churn-out-up-to-10-multi-modality-drug
